Kenvue (NYSE:KVUE) woke up on July 13 with an old legal threat suddenly alive again. A federal appeals court revived more than 500 private lawsuits tied to the Tylenol autism lawsuit saga, reopening claims that prenatal acetaminophen use is linked to autism or ADHD. The timing couldn’t be more inconvenient: Kimberly-Clark (NASDAQ:KMB) is working toward closing its acquisition of Kenvue, a deal valued at more than $40 billion. Shareholders approved the transaction in January, with closing expected during the second half of 2026.
That sounds explosive, but the courtroom reality is more limited. The appeals court did not rule that Tylenol causes autism or ADHD. It decided that three previously excluded experts should be allowed back into the litigation, while the exclusion of two other experts remained in place.
Still, legal costs don’t wait for a final verdict. Neither does consumer anxiety. The bigger question is whether this ruling changes the economics of Kimberly-Clark’s largest strategic deal.
The Court Reopened The Door — But Did Not Decide The Science
The appeals court reopened the evidence gate. It did not settle the underlying medical debate.
The three-judge panel found that the lower court went too far when excluding testimony from three plaintiffs’ experts, ruling that scientific disagreement alone didn’t justify keeping their opinions out. The cases now return to the district court for further proceedings.
That’s a procedural win for plaintiffs, not a finding of liability. They must still prove the evidence is reliable and legally sufficient, and connect individual injuries to the alleged exposure. In that sense, the Kenvue autism lawsuit fight remains far from any final determination of causation.
The scientific picture stays contested. The FDA has said some studies suggest an association, but causation hasn’t been established. The Society for Maternal-Fetal Medicine reached a firmer conclusion in June 2026, stating the available evidence does not establish a causal relationship — and it continues to recommend acetaminophen as a first-line option for pain and fever during pregnancy.
Kenvue stands behind Tylenol’s safety. It plans to challenge the experts again and is exploring its options following the decision.
Why The Revived Tylenol Autism Lawsuit Creates Costs Before Any Verdict
A company doesn’t need to lose a trial for litigation to get expensive.
More than 500 revived cases can mean years of discovery, expert reviews, depositions, and court hearings. Additional state cases may move separately alongside them. Management attention becomes its own cost, especially with senior leaders simultaneously handling a major corporate combination.
Kenvue’s March 2026 filing offered a balanced assessment. The company did not expect its legal matters, after recorded liabilities, to materially damage its overall financial position — but it warned that higher accruals could materially affect earnings and cash flow in a given period, and that the outcome of product liability litigation remains difficult to predict. In other words, the Tylenol autism lawsuit could sting individual quarters without necessarily threatening the company’s overall footing.
That uncertainty lands after an already difficult stretch. In the second quarter of 2025, organic sales declined 4.2%. Adjusted operating income fell 4.5%, and adjusted earnings dropped to $0.29 per share from $0.32. Management also cut its full-year sales and earnings outlook. Kenvue was already managing inflation, retailer inventory swings, above-benchmark overhead, and possible tariff costs — the litigation doesn’t create the turnaround challenge, but it adds another moving piece to it.
Tylenol’s Brand Strength Raises The Stakes
These aren’t lawsuits about a forgotten product sitting in Kenvue’s portfolio. They involve one of its most important consumer brands.
During its August 2025 earnings call, management described Tylenol as Kenvue’s largest Self Care brand, noting 12 consecutive quarters of U.S. market-share improvement for Adult Tylenol and calling it the leading brand recommended by healthcare professionals. Kenvue had been backing that momentum with wider distribution, brand campaigns, and new products, including Tylenol Precise Nighttime and dye-free Children’s Tylenol with natural apple flavor.
That strength cuts both ways. A trusted brand can carry enough loyalty to withstand years of negative headlines. But a controversy touching pregnancy and childhood development reaches further than an ordinary product complaint — and a resurfacing Tylenol autism lawsuit puts that brand resilience under renewed scrutiny.
Kenvue’s own turnaround plan placed consumers at the center: household penetration, repeat purchases, healthcare-professional support, and visibility across stores and online channels. A recurring court battle risks shifting the Tylenol conversation away from pain relief and toward disputed safety claims. There’s no evidence yet that the revived cases will materially dent sales, and Tylenol’s earlier share gains suggest real brand resilience — but Kimberly-Clark is acquiring that consumer trust alongside the factories, products, and cash flows.
Kimberly-Clark’s Contract Offers More Protection Than The Headline Suggests
The merger agreement may be the most important detail in this entire story.
Its public definition of a material adverse effect contains an unusually specific carve-out: effects tied to Kenvue’s acetaminophen products and autism or ADHD allegations generally cannot be used to determine whether a material adverse effect has occurred, with an exception for certain matters listed in a confidential disclosure letter.
In plain English, the revived Tylenol autism lawsuit cases likely don’t give Kimberly-Clark a simple contractual exit from the transaction. The public agreement also requires Kenvue to keep Kimberly-Clark informed of major litigation developments, with Kimberly-Clark able to review information and provide input before closing. That structure signals the buyer knew this litigation risk was part of the package going in — Kimberly-Clark has said it evaluated the deal with scientific, regulatory, legal, and other experts.
Normal closing requirements still apply: regulatory approvals, accurate representations, contractual performance, and the absence of legal orders blocking the merger. So the appellate ruling may raise costs and complicate public perception — and possibly integration planning — without automatically stopping the deal. The public documents don’t show any built-in price reduction tied to this ruling.
Final Thoughts
The revived lawsuits create real risk, but they don’t establish that Tylenol caused autism or ADHD, and they don’t appear to hand Kimberly-Clark an easy exit from its acquisition agreement.
Kenvue’s valuation reflects that mixed picture. As of July 13, 2026, the company traded at 2.92x LTM enterprise value to revenue, 2.41x sales, and 12.87x EBITDA. It also traded at 14.86x EBIT and 22.89x diluted earnings. Those multiples sit below Kenvue’s June 2025 levels, when its LTM EV/EBITDA multiple was 14.87x and its diluted P/E stood at 37.86x. The valuation has compressed, but it doesn’t resemble a distressed-company valuation — current multiples still credit Kenvue’s brand portfolio, margins, and expected transaction support, while leaving limited room for unexpected legal costs or weaker brand performance.
For now, the Tylenol autism lawsuit ruling looks more likely to complicate Kimberly-Clark’s acquisition than derail it. The next district-court proceedings, litigation reserves, consumer behavior, and remaining regulatory approvals will determine whether that assessment changes.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
